Investor Alert: Securities Fraud Class Action Lawsuit Filed by Bernstein Liebhard LLP

If you are a current or former shareholder of Sarepta Therapeutics, Inc. (NASDAQ: SRPT), you may be wondering whether you should participate in a class-action lawsuit. This legal action involves allegations of misleading statements made by the company regarding the effectiveness of its drug, eteplirsen, which is used to treat Duchenne muscular dystrophy (DMD).

The lawsuit claims that Sarepta Therapeutics made false and misleading statements about eteplirsen’s efficacy in treating DMD, which caused the company’s stock price to be artificially inflated. This alleged misconduct has led to financial harm for shareholders who relied on these statements when making investment decisions.

Investors who purchased Sarepta Therapeutics stock between April 29, 2014, and April 28, 2016, may be eligible to participate in the class-action lawsuit. The lawsuit seeks to recover financial losses suffered as a result of the alleged fraudulent activity.

While participation in a class-action lawsuit may seem like a straightforward way to seek compensation for financial losses, there are several factors to consider before deciding whether to join. It is essential to weigh the potential benefits of participating in the lawsuit against the possible drawbacks.

One consideration is the likelihood of success in the lawsuit. Class-action lawsuits can be complex and may take years to resolve. Even if the lawsuit is successful, the amount of compensation received by individual shareholders may be relatively small, particularly when divided among a large group of plaintiffs.

Another factor to consider is the cost of participating in the lawsuit. While some class-action lawsuits are handled on a contingency basis, meaning that legal fees are only paid if the lawsuit is successful, there may still be out-of-pocket costs associated with participating. It is crucial to understand these potential costs before deciding to join the lawsuit.

Additionally, participating in a class-action lawsuit may require a significant amount of time and effort on the part of shareholders. This could involve providing documentation of stock purchases, attending court hearings, and staying informed about the progress of the lawsuit. Shareholders should carefully consider whether they are willing and able to commit the necessary time and resources to participate fully in the legal process.

Ultimately, the decision of whether to join a class-action lawsuit against Sarepta Therapeutics will depend on each individual shareholder’s circumstances and priorities. Before making a decision, it is essential to consult with a qualified legal professional who can provide guidance and advice based on the specific details of your situation.